SCP Vitalife is a venture capital firm focused on life sciences investments in Israel and the United States. The firm seeks to invest in early to mid-stage life sciences companies with exceptional technologies or other proprietary advantages. SCP Vitalife allocates over half of its investment capital to investments in Israeli companies or companies that have significant R&D and operational ties to Israel. The remainder of the fund's investment capital is allocated to companies based in the United States. The fund's target initial investment size is between $3 million and $7 million, with a typical total investment of $7 million to $15 million over the lifespan of the investment.